Li Su, Gosling Martin, Poll Chris
Novartis Institutes for Biomedical Research, Novartis Respiratory Research Centre, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK.
Pflugers Arch. 2005 Oct;451(1):43-52. doi: 10.1007/s00424-005-1465-8. Epub 2005 Aug 3.
Although the TRPC members of the mammalian transient receptor potential TRP cation channel family were the first to be described in 1995, the depth of knowledge of TRPC channels has fallen behind that of their counterparts in the TRPV and TRPM subfamilies in the intervening years. The complexities and controversies of TRPC channel composition and regulation have hindered their progress as therapeutic targets in the drug discovery environment to date, however embracing these challenges as opportunities may bring TRPC channels to the forefront of the discovery of novel therapies for many diseases. These challenges and opportunities of exploring TRPC channels as therapeutic targets are highlighted and discussed in this review with respect to respiratory diseases.
尽管哺乳动物瞬时受体电位(TRP)阳离子通道家族中的TRPC成员于1995年首次被描述,但在随后的几年里,TRPC通道的知识深度落后于TRPV和TRPM亚家族中的同类通道。TRPC通道组成和调节的复杂性及争议阻碍了它们至今在药物发现环境中作为治疗靶点的进展,然而将这些挑战视为机遇可能会使TRPC通道在许多疾病新疗法的发现中处于前沿位置。本综述针对呼吸系统疾病着重介绍并讨论了将TRPC通道作为治疗靶点所面临的这些挑战和机遇。